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CLINICAL REPORT
Life-long Course and Molecular Characterization of the Original
Dutch Family with Epidermolysis Bullosa Simplex with Muscular
Dystrophy due to a Homozygous Novel Plectin Point Mutation
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Plectin is one of the largest and most versatile cytolinker
proteins known. Cloned and sequenced in 1991, it was
later shown to have nonsense mutations in recessive
epidermolysis bullosa with muscular dystrophy. A
dominant mutation in the gene was found to cause
epidermolysis bullosa simplex Ogna without muscular
dystrophy. Here we report the DNA sequencing of the
plectin gene (PLEC1) in a Dutch family originally
described in 1972 as having epidermolysis bullosa with
muscular dystrophy. The results revealed homozygosity
for a new plectin nonsense mutation at position 13187
and its specific 8q24 marker haplotype profile. Western
blotting of cultured fibroblasts and immunofluorescence
microscopy of skin biopsy confirm that the plectin protein
expression is grossly reduced or absent. A summary of
the life-long clinical course of the two affected brothers
homozygous for the new E1914X mutation is given. Key
words: EBS-MD; genotype-phenotype; nonsense muta-
tion; plakins; plectin; PLEC1.
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Epidermolysis bullosa simplex with muscular dystrophy
(EBS-MD) is a rare recessive disease associated with
plectin deficiency (1) and caused by nonsense muta-
tions, small deletions or insertions in the PLEC1 gene
(2 – 14) coding for the protein plectin. Targeted
inactivation of the plectin gene in mice caused a
phenotype similar to that of human EBS-MD patients
(15). Plectin, a member of the plakin family, acts as a
versatile cytoskeletal linker protein (16). It is expressed
in epidermal cells, muscle cells and various other tissues
(19). Plectin was first cloned and sequenced from rat
(18) and later from man (19) and mouse (20). The only
dominant mutation described in PLEC1 has been
shown to cause the rare blistering skin condition
epidermolysis bullosa simplex Ogna (EBS-O) (21).
The first detailed clinical report on epidermolysis
bullosa with muscular dystrophy was published in
1972 in Dutch by the neurologist C. J. de Weerdt
and dermatologist S. Castelein, who named it EB
dystrophica because of skin sequelae and nail dystro-
phies (22). Electron microscopy of the skin of the two
affected brothers revealed low intraepidermal basal
cell blistering and hemidesmosomes with hypoplastic
attachment plates and impairment of keratin filament
insertion into the inner hemidesmosomal plaque (23).
This blister pathogenesis differed from both dystrophic
and junctional EB (23 – 26). The group was initially
denoted ‘‘pseudojunctional’’ (P-JEB), but has later been
renamed EBS-MD (27).
Altogether 15 patients with individual mutations
suffering from EBS-MD have been described (2 – 14),
all suffering from a generalized blistering skin condi-
tion or fragile skin with blistering due to trauma at
birth or in infancy, nail dystrophy and a severe mus-
cular dystrophy resembling the limb-girdle type with a
variable onset from infancy (delayed walking) to their
early 30s.
We report Western blotting of fibroblast cultures,
immunofluorescence microscopy of the skin, and mole-
cular findings in the genomic plectin (PLEC1) locus
and its flanking 8q24-haplotype in the original Dutch
EBS-MD family. The life-long clinical course of the
two adult patients is also summarized.
PATIENTS AND METHODS
Patients
The Dutch family (NEB1) first published in 1972 (22)
comprises both lethal and non-lethal cases. The parents did
not report consanguinity, but both knew of ancestral lines to
rural Western Germany. Later other relatives reported that
{Dr W. P. de Groot (1919 – 1999) was consultant at the Department
of Dermatology at the Free University of Amsterdam 1964 – 1984.
This article is dedicated to his memory.
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the parents were third cousins, hence the inbreeding
coefficient is 0.00391 for the patient generation.
In a sibship of 14, 3 girls and 3 boys had generalized
blisters from birth, and 4 of those died in infancy (see Fig. 4
for a partial pedigree). The 3 girls (nos. 3, 6, 8) died within a
few weeks because of their skin condition; the boy (no. 12)
died at 5 months of age due to pneumonia. He was recalled to
have fewer blisters than his affected siblings. Another boy
(no. 2) looked normal at birth, but was never able to move
out of bed, never learned to walk or talk, had epilepsy and
was severely psychomotorically retarded. He died at 10 years
of age.
Two boys with EB (nos. 9, 11) grew up and both developed
progressive muscular dystrophy from age 15 (no. 11) and age
17 (no. 9), respectively, but none of their 7 healthy living
siblings did so. Based on the suspicion that this family did not
have dystrophic EB, but rather a non-Herlitz EB junctional
type of the disease, their neurologist, Dr. de Weerdt, kindly
arranged for two of us (CPdG, TGD) to see the whole family
in their home town in North Holland, the Netherlands,
in 1982. In addition to a detailed clinical history from the
parents and the two patients, blood samples for classical
genetic marker testing and skin shave biopsies for fibroblast
cultures were taken of all 11 living family members. The
parents and the 2 affected boys had normal karyograms
(analyses by Anton Brøgger, Oslo, Norway).
The patients were followed up by one of us (C. J. de
Weerdt) in their home town and had frequent admissions
until their deaths in 1990 (no. 9, 44 years) and 1995 (no. 11,
47 years). A skin biopsy for immunofluorescence study was
taken several hours post-mortem from patient no. 11.
Autopsies were not done.
Immunofluorescence study
Skin samples were processed for immunofluorescence as
previously described (28). The primary antibodies raised
against human and rat antigens are listed in Table I. In
combination with primary mouse IgG we used biotinylated
horse anti-mouse IgG (Vector Laboratories, Inc., Burlingame,
CA, USA) and FITC (fluorescein isothiocyanate) conjugated
neutravidin (Southern Biotechnology Associates (SBA), Inc.,
Birmingham, AL, USA). For the primary mouse IgM anti-
body we used FITC conjugated goat anti-mouse IgM (SBA).
In combination with primary rat IgG we used FITC-
conjugated goat anti-rat IgG (SBA). Digital fluorescence
images of tissue sections were obtained with a Leitz
Orthoplan microscope equipped with a video imaging
system with exposure time control board designed for the
detection of low levels of fluorescence (29).
Fibroblast cultures
Fibroblasts stored in liquid nitrogen after establishment
in 1982 were recovered and used for DNA extraction by
standard protocols from all 11 family members and for plectin
protein expression from 2 patients (nos. 9 and 11) and one
unaffected sibling (no. 10). Primary fibroblasts derived from a
non-EB-MD patient (EB107-1) were used in the preparation
of control lysates for Western blotting.
Western blotting
Cultured patient and control primary fibroblasts were lysed
directly in hot 26 PAGE sample buffer and run on SDS 3.5%
polyacrylamide mini gels. Separated proteins were transferred
to PVDF membranes (Millipore, Bedford, MA, USA) and
membranes blocked with 3%BSA over night. Immunodetec-
tion of plectin on the blots was carried out with mAbs 10F6
and 5B3, followed by goat anti-mouse antibodies conjugated
to alkaline phosphatase (Promega, San Luis Obispo, CA,
USA). Plectin purified from cultured rat glioma C6 cells was
used as size marker.
Genetic markers and linkage studies
After plectin was reported in situ assigned to 8q24 (19)
we typed the then most 8q telomeric DNA marker, the
tetranucleotide repeat D8S373 (23). Recently, we added the
following 8q-assigned dinucleotide Genethon STR-markers:
D8S274, D8S1717, D8S1836, AFMa128xh5, D8S1925 and
D8S2334. The primers were as specified from Genethon and/
or the Genome Data Bank (gdbwww.gdb.org) and labelled
with FAM or HEX. Fragment sizes were determined on
an ABI 377 sequencer. The results were entered in Cyrillic
format. Lod scores for linkage analysis were calculated where
needed by standard methods.
DNA sequencing
Plectin sequences deposited in GenBank (acc. nos. U63610;
Z54367; X59601; U53204; and NM_000445) were used to
design PCR primers that would yield overlapping 400 –
600 bp-long DNA fragments covering the sequence from the
start of exon 2 to the end of exon 32 (19) (exon 33 in the
McLean et al. terminology (3)), and skipping only the longest
introns.
All PCR primers were designed as described earlier (21).
The PCR products were purified either using the QIA quick
PCR Purification Kit (Qiagen) or the PCR product pretreat-
ment kit (USB) and subsequently sequenced using PRISM
AmpliTaq FS Dye Primer Cycle Seq. Kit (Perkin Elmer) and
run on the ABI 377 automatic sequencer. Sequences were
aligned and compared using Sequencher 4.1 from Gene Codes
Corporation.
Mutation detection by restriction enzyme
The restriction patterns after 4 h (at 37‡C) HinfI digestion of
exon 31 DNA amplified with the PLE47F/PLE48R primers
(PLE47F: AGGACGAGAGCCAGCGTAAG; PLE48R:CCT
CTGCTTGGACTTCTC) followed by nested PCR with the
PLE47F/R primers (PLE47F: AGGACGAGAGCCAGCGTAAG;
Table I. Rodent antibodies used for immunofluorescence
microscopy of skin (35, 36)
Antigen (source) Antibody Isotype
keratin 5 (Hu) AE14 IgG1
keratin 14 (Hu) RCK107 IgG1
500-kD HD-1 (Hu) HD121 IgG1
plectin (I-2) (Rt) 6C6 IgG2
plectin (II) (Rt) 10F6 IgG 1
plectin (III-1) (Rt) 5B3 IgG 1
plectin (III-1) (Rt) 5C10 IgM
BP230 (Hu) R815 IgG 1
BP180 ic (Hu) 1A8c IgG 1
integrin a6 ec (Hu) GoH3 IgG 2a
integrin b4 ec (Hu) 439-9B IgG2
laminin-5 g2 (Hu) GB3 IgG1
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PLE47R:TTCCAGCTCCTGCCGTTTC), were read after a
2 h run at 70V on a 10% PAGE gel.
RESULTS
Clinical features and course of the disease
The course of the disease shared the following skin
manifestations: Blisters at birth and in 2 of them speci-
fically on the fingers, soon widespread occurrence of
new blisters, buttocks invariably affected with sores.
Lifting up the baby in the usual way induced blisters on
lateral thorax in a pattern showing the finger grips. No
blister sequelae, including no miliae, remained upon
healing. In childhood, both of them had had attacks of
eye irritation. No. 9 had a hoarse voice throughout life.
By age 33, no. 11 had lost all his permanent teeth, while
his 38-year-old brother, no. 9, had decayed teeth
similar to those often seen in severe-dystrophic EB.
Both patients had dystrophic nails (Fig. 1), no oral
blistering but new blisters at 2 – 4 week intervals on
the peripheral extremities, leaving many spots of pale
atrophic skin often surrounded by hyperpigmentation.
No. 11 was deaf in his right ear and had reduced
hearing in the left. From age 15 he had experienced
slowly increasing muscular weakness. At first he had
problems getting out of bed without the help of his
arms, and the knees tended to sink together when he
tried to get up from a lying position. Muscular biopsy
of the m. quadriceps at that time revealed extensive
variation of the diameter of muscle fibres – with big
rounded fibres with several central nuclei and signs of
regeneration.
At 33 years, the muscular atrophy was still most
striking at the proximal extremities (limb-girdle-like;
Fig. 1), but included facial muscles, ptosis, Bell’s
phenomenon and bulbar dysarthria. At age 46 he
could still walk, but had a typical waddle and drop
foot. He died the same year as a result of respiratory
insufficiency probably caused by his muscular disease.
The older brother (no. 9) experienced the same
muscular dystrophy from age 17. He had recurrent
pulmary infections during childhood and died at 44
years of age because of respiratory insufficiency and
kidney failure.
Fig. 1. The younger brother (no. 11) with EBS-DM at age 33
years. Note the generalized muscle atrophy with predominantly
limb-girdle distribution, faint atrophic skin areas and superficial
blood blisters dorsally on the fingers and hands, with variable nail
dystrophies.
Fig. 2. Immunofluorescence microscopy of the skin of no. 11 with
recessive epidermolysis bullosa simplex with muscular dystrophy
(A, C, E) and of a normal human individual (B, D, F). The nuclei
are counterstained in blue with bisbenzimid. Anti-HD1/plectin anti-
body does not bind to the epidermal basement membrane zone in
the patient (A). Anti-plectin antibodies (5B3 and 5C10) also do not
bind to this region (C, E). The staining with anti-plectin 5C10 anti-
body at the cell periphery in the suprabasal layers is also lost,
whereas the perinuclear staining in epidermal cells, fibroblasts and
endothelial cells remains conserved (E). Bar is 10 mm.
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Absence of plectin in skin and fibroblast cultures
Immunofluorescence microscopy of the skin: mono-
clonal antibody (mAb) HD-121 to 500-kD HD-1/
plectin (30) did not bind to the epidermal basement
membrane zone (EBMZ) in patient no. 11 (Fig. 2A, B).
Also mAbs 10F6, 5B3 (Fig. 2C, D), 6C6 and 5C10
(Fig. 2E, F) against plectin did not bind to the EBMZ,
although some epitopes appear to remain in the
suprabasal layers (6C6) or perinuclear region (5C10)
of the epidermis.
Knowing that the patient’s skin lacks plectin, the
tissue distribution of other hemidesmosome components
becomes important. Basal keratins 5 and 14 were nor-
mally present in the basal epidermal cells. The 230-kD
and 180-kD bullous pemphigoid antigens, as well as the
integrin subunits a6 and b4 and laminin-5, were all
unreduced and normally polarized in the EBMZ (data
not shown).
Western blotting: When lysates from cultured fibro-
blasts from the patients (nos. 9 and 11) were subjected
to Western blotting, no protein band at the position of
plectin was seen, contrary to lysates from an unaffected
sibling (no. 10) and control lysate (Fig. 3).
Linkage and haplotype studies
All family members were homozygous 1-1 in glutamate
pyruvate transaminase (chromosome 8q24) (Fig. 4).
When short tandem repeat markers became available,
the two common limb-girdle muscular dystrophy loci
(on chromosome 2 and chromosome 15), the two
laminin-5 loci tested (on chromosome 1q) and the
collagenase locus (on chromosome 11q) were also
excluded as candidate loci.
When plectin became assigned to chromosome 8q24,
we first tested D8S373, most telomeric on the tetra-
nucleotide marker CHLC (Collaborative Human Link-
age Center) map, and confirmed full co-segregation
with the EBS-MD disease (23). We have elaborated the
extended 8q24 haplotypes, as shown in Fig. 4. During
our current plectin DNA sequencing studies we have
observed several polymorphisms, including an inser-
tion/deletion polymorphism with alleles S and F (to
be published). In Fig. 4 one intragenic plectin marker
on each side of the disease mutation is flanked by
short tandem repeat markers located according to our
ongoing 8q24 fine mapping. This reveals an identical
long haplotype from both parents strongly suggesting
identity in descent and therefore predicting homozyg-
osity for an 8q24 disease-causing mutation.
Mutation detection by gene sequencing and restriction
enzyme
DNAs from two unaffected siblings (nos. 7 and 13)
and one patient (no. 11), representing one normal
and one disease-carrying chromosome (as shown in
the haplotype analysis), together with DNAs from 12
other haplotypes (21), were subjected to systematic
sequencing from exon 2 to exon 32 (see Methods). A
new plectin nonsense mutation was found using the
Ple48 primer (PLE48F AAACGGCAGGAGCTG-
GAAG: PLE48R) (Fig. 5). The substitution which
was verified homozygous in both patients is a GwT
transversion at genomic position 13187 (GenBank
Fig. 3. Immunoblotting of fibroblast cell lysates from EBS-MD patients. (A) Coomassie staining of lysates from control (unaffected sibling
no. 10) and affected patients nos. 9 and 11. Arrows point at position of plectin band. (B) Anti-plectin immunostaining of Western blots
using mAbs 5B3. Lane 1: purified rat glioma C6 plectin; lane 2: EB 107-1 patient (positive control); lane 3: unaffected sibling no. 10; lanes
4 and 5, EBS-MD patient nos. 9 and 11.
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accession no. U63610), corresponding to cDNA posi-
tion 5740 (codon 1914) in GenBank accession no.
Z54367 (position 5461 in cDNA U53204) located in
exon 31 (exon 32 in (3)). This mutation leads to a shift
from GAGwTAG resulting in the substitution of
glutamic acid codon with a stop codon (E1914X) in the
plectin polypeptide. This base substitution abolishes a
normal HinfI restriction site and allows a restriction-
based identification of the mutation in all carriers of the
NEB1 family (Fig. 6). Normal DNA has a restriction
site splitting the 156 bp nested PCR product into
106 bp and 50 bp fragments (including m13 tail),
whereas the EBS-MD mutation abolishes this restric-
tion site leaving the pattern of the homozygote (no. 11)
with unsplit fragments similar to undigested fragments.
One hundred Norwegian random chromosomes (50
individuals) lacked this mutation. Homozygosity for
the stop mutation in both affected individuals and
heterozygosity in unaffected family members are in full
accordance with the distribution of 8q24 haplotypes,
supporting that this nonsense point mutation is in fact
the cause of EBS-MD in this family.
Further downstream another mutation was found
using the PLE57 primer (PLE57F: TGTGAAGGA-
GGGTGTGGTG; PLE57R: CTGCCGTGAAGTAT-
TCCG). This is an AwG substitution in position 16455
in genomic DNA (U63610) creating a restriction site
for NgomIV. It corresponds to cDNA position 8900
Fig. 4. The 8q24 haplotypes in the NEB1 family. The given order is based on our ongoing family and radiation hybrid studies. Note the
long identical haplotype shared by both parents and carrying both the new disease mutation 13187 G-wT (E1914X) and the 16455 A-wG
substitution.
Fig. 5. DNA sequencing revealing a GwT mutation in the affected
proband NEB1-9 (a), G/T heterozygosity in non-affected family
members NEB1-7 (b) and NEB1-13 (c), whereas the healthy control
shows homozygous G (d).
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(codon 2967) in Z54367 and position 8621 (codon 2857)
in U53204. This change results in alteration of the
amino acid tyrosine (TAC) to cysteine (TGC). Of 140
chromosomes, 7 carried G, shown by NgomIV typing,
which reflects a polymorphism (A~0.95, G~0.05).
DISCUSSION
All EBS-MD mutations known to us up to December
2002 are detailed in Table II. Our novel genomic
mutation 13187G-wT or cDNA 5740G-wT, changing
a GAG glutamic acid codon to a UAG termination
codon (E1914X), is located in exon 31 (19) between the
Italian 5728C-wT (Q1910X) (5) and the Japanese
5806C-wT (Q1936X) (9,10) EBS-MD mutations. The
skin of patient no. 11 with the homozygous PLEC1
late stop mutation makes mapping of monoclonal
antibodies in the absence of plectin possible. Note-
worthy is the remaining expression of plectin epitopes
in the suprabasal layers (6C6) of the epidermis and
Fig. 6. The pathogenic EBS-MD 13187 G-wT plectin mutation identified in a HinfI restriction enzyme test, verifying the mutation in rela-
tives carrying the same haplotype. In controls the 156 bp nested PCR product splits into 106 and 50 bp fragments (including m13 tail),
whereas the EBS-MD mutation abolishes this restriction site (see no. 11).
Table II. Reported disease mutations in the plectin gene (PLEC1) as in December 2002. The total of 34 alleles depict 23
different recessive EBS-MD mutations and one dominant EBS-O mutation. Updated after Table 145.3 in ref. 34
McLean et al. (3)









exon 10 1008uns3 Austria 1 3
exon 23 2719del9 Japan 2 4,1
exon 23 2745-9del21 France 1 11
exon 25 3156C-wT Q1053X Japan 1 9
exon 32 Q1408X Austria 1 13
exon 32 4359ins13 Japan 1 8,1
exon 32 4416delC Japan 1 8
exon 32 5069del19 England 2 7
exon 32 5083delG France 1 11
exon 32 5148del8 Spain 2 3
exon 32 5188C-wT Q1713X Germany 1 10
exon 32 5461G-wT E1804X Netherlands 2a This study
exon 32 5728C-wT Q1910X Italy 2 5
exon 32 5806C-wT Q1936X Japan 1 9,1
exon 32 5866delC Japan 2 4,6
exon 32 5905del2 Italy 2 4
exon 32 5907ins8 Italy 2 2
exon 32 6049C-wT R2000W Norway, Germany 2b 21
exon 32 6064G-wT E2005X Spain 1 11
exon 32 7102C-wT R2351X Germany 1 13
exon 32 7261C-wT Q2421X Japan 1 9,1
exon 33 12633ins4 Japan 1 9,1
exon 33 13429A-wT K4460X 1 11
exon 33 13524 2c 14
aIn U63610 (gDNA): 13187; in Z543067 (cDNA): 5740G-wT and E1914X.
bIn U63610: 13775; in Z543067: 6328C-wT and R2110W.
cIn U63610: 21358; in Z543067: 13805.
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perinuclear (5C10) region in all cells of the skin. These
antigens may represent alternative splice variants of
plectin, which is distributed in most tissues. Western
blotting of the huge plectin molecule often results in
a ladder of bands that may not always be degradation
products, but instead alternative splice variants. Similar
to other cases of EBS-MD, it should be noted that
plectin mRNA was significantly reduced (to ,5% of
its normal level), as determined by RNase protection
assays using fibroblasts derived from patient nos. 9
and 11 (data not shown).
The absence of plectin did not result in altered
distribution of other hemidesmosome components
such as BP230, BP180, and integrin a6b4, nor in its
associated intermediate filaments keratins 5 and 14.
Thus plectin is not essential for the recruitment of these
hemidesmosome components (31).
Compared to extensive tissue sampling and examina-
tions recently performed on young adult patients (14),
we only had fibroblasts and 2 postmortem skin samples
available for study. However, the size of the extensively
sampled family 2 decades ago made it ideally suited for
gene mapping by linkage. Unfortunately both parents
happened to be homozygous in the GPT isozyme
system, so no association was made with the GPT-
linked dominant epidermolysis bullosa simplex Ogna
(32) back in 1982. EBS-Ogna is now explained by an
exon 31-specific base substitution and plectin amino
acid exchange (R2110W) (21).
In the history of clinical delineation of Mendelian
disease the coexistence of different organ signs and
symptoms has led to prolonged discussions of (a) the
chance co-occurrence of independent diseases, (b) the
pleiotropic effects of a single disease mutation, or (c)
the close genetic linkage of different Mendelian dis-
eases. This is also the case with EBS-MD.
When the Dutch report (22) of EB dystrophica
with muscular dystrophy was later complemented by
a ‘‘similar’’ association in a Finnish family with EBS
and muscular dystrophy (25), both chance coincidence
and linkage of two separate loci became less likely,
but classification of the EB involved was at stake.
Like Anton-Lamprecht’s ultrastructural results in the
Dutch family, the Finnish workers saw the low basal
cell intraepidermal origin of the blistering. The
intraepidermal pathogenesis led to their term EB
simplex, although the clinical signs were similar to
junctional EB, hence the original term pseudojunc-
tional EB (23, 24). The term EBS-DM was recom-
mended by Fine et al. (27). The low intrabasal cell
split level categorizes this form as EBS (27). The same
very low split level within the basal cell is also seen in
EBS due to a ITGB4 mutation deleting part of the
cytoplasmic tail of integrin beta4 (33). When plectin
first came into focus, our initial D8S373-typing
revealed full linkage to this at that time the most
telomeric marker on the genetic chromosome 8q map
(23).
The extended haplotypes (Fig. 4) define a region of
8q24 for which the EBS-MD patients of the family are
homozygous and haplotype identical from both par-
ents. The considerable length of the haplotype common
to both parents is explained by the inbreeding (parents
3rd cousins), but we do not know if this inbreeding line
includes the initially reported West German ancestors.
When other detected EBS-MD mutations are likewise
haplotyped, this will give a rapid indirect way of pin-
pointing previously known mutations in new patients.
In the review by Anton-Lamprecht & Gedde-Dahl
(34) no specific Dutch origin mutations, but 2 pre-
viously reported exon 31 German mutations (5188C-
wT, Q1713X: and 7102C-wT, R2351X), are described
(12). To this can be added the exon 32 North-East
German 16 basepair insertion mutation 13803ins16
which leads to loss of the normal 35 last amino acids in
the plectin polypeptide and thereby the keratin binding
motif (14).
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